GSK Just Paid $10.6 Billion for This Precision Oncology Bet — Here’s What It Signals
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
SpaceX Just Went Public — Here’s What Traders Need to Know Right Now
SPCX debuted on the Nasdaq June 12 at $135, surged 19% to $161. The largest IPO in history is now a live trading instrument — and the market is still processing it.
The Healthcare Sector Has Been Left for Dead. That’s the Setup Bargain Hunters Have Been Waiting For.
Three years of underperformance, a 20% valuation discount, and a mean-reversion case that’s getting harder to ignore.
AI Needs a Lot of Electricity. The Grid Can’t Keep Up. Here’s Where the Money Is Going.
The power bottleneck is the most underpriced constraint in the AI buildout — and utilities are finally getting noticed.
The Defense Spending Supercycle Isn’t Slowing Down. Here’s How to Play It Without Overpaying.
NATO just hit record budget levels. Global military spend crossed $2.63 trillion. And the primes are still trading at reasonable multiples.
Salesforce Beat the Quarter, Then the Stock Sold Off. Here’s What the Options Market Already Knew.
CRM delivered record Q1 FY2027 results powered by Agentforce — but the price action tells a more complicated story that options traders were already pricing in.
SMCI Just Dropped 28% in Two Days. Here’s What the Options Market Is Telling You Right Now.
A $7 billion equity raise, $39 billion in AI server orders, and a stock in freefall — the setup is messier than it looks.
Anthropic’s Near-Trillion Dollar IPO Filing Is Repricing Everything. Here’s What Investors Actually Own.
The Claude maker confidentially filed its S-1 at a $965B valuation. The real story isn’t Anthropic — it’s what this does to the listed AI complex.
ORCL Reports Tonight. The Options Market Is Already Pricing a 13% Move.
Oracle’s Q4 earnings hit after close — and the derivatives market is positioning for a major swing in either direction.
MRVL: The S&P 500 Inclusion Trade, the Jensen Huang Endorsement, and What the Options Market Is Actually Pricing
Marvell Technology just had the wildest week in the chip sector. The question now isn’t whether the story is real — it’s whether the market has already paid for it.